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If the arguments to support a recommendation are partly implicit, the free exchange of ideas between discussants 
can be hampered. In this paper, we will focus on the potential pitfall for clinicians when informing patients about 
treatment options:  implicit persuasion. We will describe a set of implicitly persuasive behaviors observed during 
decision-making consultations, and reflect on how these behaviors could undermine efforts to stimulate patient 
participation in decision-making. We will also reflect on possible explanations for why clinicians exhibit such 
behaviors.  
 




1. Information provision is a key component of the decision-making process 
Medical decision-making is a complex process that requires an exchange of information between healthcare 
providers and patients. Patients (often) lack the bio-medical knowledge to be able to form the informed treatment 
preference needed to make a treatment decision. Therefore, they rely on their doctor to provide them with the 
information and advice based on bio-medical knowledge and clinical experience. The clinician needs 
information about the patients’ goals and priorities regarding the management of their illness, to be able to help 
patients weigh the pros and cons of available options and to provide this advice.  
 The objective of decision-making consultations is for patients and clinicians to arrive at a treatment plan 
that is in line with the patient’s goals and priorities. To achieve this, clinicians’ need to 1) ascertain patients’ 
goals and priorities regarding the management of their illness, and 2) provide them with information about the 
pros and cons of relevant options. Particularly when faced with preference-sensitive treatment decisions, i.e., 
decisions for which there is no best option from a medical perspective, it is crucial to go through these steps 
adeptly. In the context of such decisions, the Shared Decision Making approach (SDM) is widely advocated. 
SDM consists of four key steps (Stiggelbout et al. 2015:1172-1179), namely: 
1. Creating choice awareness: Clinicians need to explicitly communicate to patients that a treatment 
decision needs to be made, and that the patient’s input is indispensable.  
2. Information provision: For the patient to be able to participate in the decision-making process, clinicians 
need to inform the patient about the pros and cons of all viable treatment options – including the option 
to forego treatment if relevant.  
3. Weighing pros and cons: Clinicians need to support patients in weighing the pros and cons to determine 
which treatment option the patient prefers, or best fits the patient. 
4. Decision-making: After deliberation between doctor and patient about the pros and cons, the final 
treatment decision is made. Here, it is not relevant whether the patient, the doctor or both together make 
the final treatment decision, key is that the patient’s goals and priorities have been considered. 
 
Incorporating these key principles of SDM in the consultation, if executed competently, safeguards that the final 
treatment decision is medically sound and in line with patients’ goals and priorities. In this paper, we will focus 
on the second step of SDM - information provision. A potential barrier to patient participation is unbalanced 
information provision. Especially, when faced with preference-sensitive decisions, it is important that the 
information does not contain implicit cues suggesting that there is a right option – i.e., implicit persuasion.  
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1.1 Implicit persuasion: definition and its prevalence in clinical practice 
Even if clinicians do not verbalize a treatment recommendation or consciously steer patients towards a specific 
treatment option, their choices about what information to disclose, and the way this information is phrased, can 
suggest to patients that their doctor favors a specific option. Implicitly steering behaviors could persuade patients 
to consent to a treatment plan that does not match their goals and priorities.  
 To the best of our knowledge, Karnieli-Miller and Eisikovits (2009:1-8) were the first to systematically 
operationalize the construct implicit persuasion in the context of medical decision-making consultations. In our 
own work (Engelhardt et al. 2016:55-66), we used the framework created by Karnieli-Miller and Eisikovits as a 
starting point for a coding scheme to assess the use of implicit persuasion in oncological practice, specifically in 
the context of adjuvant systemic therapy for early-stage breast cancer. We observed multiple implicitly 
persuasive behaviors in all the 105 consultations we analyzed (median of five behaviors per consultation (range: 
2–10)). The direction of the implicit steering was predominantly toward undergoing treatment. This is 
noteworthy since 53% of the patients in our study population had stage 1 disease for which foregoing treatment 
generally is an option that will not significantly increase the probability of an unfavorable (long-term) outcome. 
 To date, besides the work by Karnieli-Miller and Eisikovits and our group, there have not been other 
studies that have systematically analyzed the use of implicit persuasion in clinical practice. In many studies of 
doctor-patient communication implicitly persuasive behaviors have been described, but they were not identified 
as such (see for example Ziebland et al. 2015:3302-3312). Also, decision aids aiming to support the shared 
decision-making process have been shown to contain implicitly persuasive language (Molewijk et al. 2008:415-
420). Evidence from systematic analyses is limited, but it seems likely that the use of implicit persuasion might 
be a widespread phenomenon in medical practice. More research is needed to get better insights into the extent to 
which implicit persuasion permeates medical decision-making. 
 
1.2 Is implicit persuasion inherently wrong? 
Given that there are indications that implicit persuasion might be pervasive in medicine, it is worth considering 
whether this is a cause for concern. Implicit persuasion is innately an undesirable phenomenon. At its core, 
implicit persuasion violates the imperative of patient autonomy, and is primarily rooted in a failure by clinicians 
to meet their duty to inform patients fully and adequately. Even if the clinician believes that steering (or 
nudging) patients towards the treatment she believes is in the patients’ best interest, it likely impedes efforts to 
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stimulate patient participation in decision-making. Implicit persuasion is particularly concerning when there is no 
best treatment option, as then, unbeknownst to them, patients are being steered towards a specific treatment 
about which it is uncertain whether it is best for them. When there is no best option from a medical perspective, 
patients’ treatment goals and priorities should be the driving force in decision-making. Implicit persuasion might 
lead patients to think that their doctor knows the right option. Due to the inherent imbalance in power in the 
doctor-patient relationship, patients might be reluctant to verbalize apprehensions they might have towards the 
implicit treatment recommendation. Patients could thereby (inadvertently) be persuaded to consent to a treatment 
that is not the most suitable for them. The discordance between their goals and priorities and the treatment they 
receive, could result in the treatment constituting an unnecessarily large burden on their quality of life, and could 
even lead to sub-optimal treatment adherence or early treatment discontinuation, which could in turn affect the 
course of their disease.  
 
2. Implicitly persuasive behaviors 
We will describe the implicitly persuasive behaviors observed during decision-making consultations in the 
context of adjuvant systemic therapy for early-stage breast cancer. All the examples described here are from our 
previously published study; the study design and population are described elsewhere in detail (Engelhardt et al. 
2016:55-66). We will first describe the setting. 
 
2.1 Clinical context 
Six out of ten breast cancer patients diagnosed between 2006 and 2012 in the Netherlands received adjuvant 
systemic therapy after the surgical removal of the main breast tumor and any metastases present in the axillary 
lymph nodes (Saadatmand et al. 2015:h4901). Adjuvant systemic therapy consists of: (1) chemotherapy for six 
months up to one year, and/or (2) endocrine therapy (i.e., tamoxifen and/or aromatase inhibitors) for at least five 
years. Adjuvant systemic treatment may improve patients’ disease-free and breast cancer-specific survival 
probability. On an individual level treatment benefit varies, with absolute benefits ranging between 1-15% (Early 
Breast Cancer Trialists Collaborative Group 1998:930-942; Davies et al. 2013:805-816). It is important to note 
that adjuvant systemic therapy is a preventative treatment, i.e., it is given to patients to potentially treat disease 
that may or may not be present (i.e., micro-metastasis which cannot be detected yet). Breast cancer is a very 
heterogeneous disease, and it is not yet possible to select patients that might benefit from treatment. Clinical 
guidelines recommend offering adjuvant systemic therapy to patients if the expected absolute treatment benefit is 
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minimally 3-5%. That minimal absolute benefit also means that it is currently deemed acceptable to treat 25 
patients to save one patient from dying due to breast cancer. Therefore, for this preference-sensitive treatment 
decision, it is imperative that patients carefully consider whether the treatment benefits outweigh the harms 
considering their goals and priorities. 
 
2.2 Category 1: Unbalanced presentation of benefits and side-effects 
A balanced presentation of the benefits and side-effects of treatment is a key component of information provision 
during consultations. This helps patients to form an idea of what undergoing treatment entails – how it can affect 
their daily lives. It is unrealistic to assume that patients who are not adequately informed are able to form a well-
informed opinion on whether the benefits of treatment outweigh the side-effects – whether a treatment option is 
worthwhile to them. We present below five implicitly persuasive behaviors relating to unbalanced information 
provision. 
 
2.2.1 Minimal number of side-effects presented. Both adjuvant chemotherapy and endocrine therapy for breast 
cancer have numerous side-effects. If we only look at the side-effects occurring often (i.e., in 1-10% of patients) 
to very often (i.e., in more than 10% of patients), each of the adjuvant systemic treatment regimens has more 
than a dozen side-effects. Therefore, we deemed the communication about side-effects in our study (Engelhardt 
et al. 2016:55-66), to be insufficient if fewer than five side-effects were communicated to patients, respectively. 
Admittedly, the cut-off of five is arbitrary, but (inter-) national clinical guidelines do not provide guidance on 
which side-effects minimally need to be communicated. Fewer than five side-effects were communicated in eight 
out of ten consultations. This held for both chemotherapy and endocrine therapy.  
 One important factor underlying the minimal communication of side-effects is the fact that information 
provision about side-effects was routinely delegated to specialized nurses and/or nurse practitioners. Oncologists 
regularly indicated – after the decision was made – that they would only briefly go through some important side-
effects, but patients would receive extensive information during the consultation with the nurse prior to the start 
of treatment. For example: “You will receive all the information [about the side-effects and procedures] from the 
specialized nurse later on… she has more time and will go into more details about chemotherapy.” Nowadays, in 
most Dutch outpatient clinics, specialized nurses act as case managers during the diagnosis, treatment, and 
follow-up of patients. Having such a constant factor is good for patients and it is a positive development that the 
nurse will go through the information with the patient. From the moment they receive the diagnosis, patients face 
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several (life-changing) decisions in short succession during a period that is emotionally and physically trying. 
However, it is important for patients to be made aware of both the benefits and harms of the treatment options 
prior to deciding about treatment.  
 Finally, in addition to meeting minimal requirements regarding the number of side-effects 
communicated, attention also needs to be paid to the quality of the description of the side-effects. We observed 
very brief and little informative discussions about the side-effects during the consultation. Frequently 
information provision about side-effects only consisted of the mention of the side-effect (see Example 1).  
 
HERE BOX WITH EXAMPLE 1 
 
2.2.2 Emphasizing the benefits or downplaying the side-effects of treatment. Repeatedly emphasizing the 
magnitude of the treatment effect whilst minimizing the side-effects or vice versa, unbalances information 
provision. We observed this behavior in half of the 105 consultations analyzed (Engelhardt et al. 2016:55-
66). For example, when oncologists stated at various points during the consultation that the probability of 
developing a recurrence without treatment is “quite substantial”, whilst also repeatedly stressing that “You 
might experience side-effects, but most patients get through treatment without too many problems”. Such 
repeated emphasis on the pros or the cons could suggest to patients that the direction of implicit steering 
indicates the right treatment option. Arguably, it is reasonable to assume that to many patients the 
clinician’s implied preference carries much weight. This could stifle patients’ own critical appraisal of the 
treatment options, as well as a discussion during the consultation of the concerns patients might have. Such 
implicitly steering behaviors are especially undesirable if no explicit advice is given, and patients only have 
their impression of the oncologist’s preference. Such impressions could be wrong, and if not verbalized, 
incorrect assumptions might end up playing a (significant) role in decision-making. 
 
2.2.3 Minimizing the treatment's impact. Utterances by oncologists can (unintentionally) minimize patients’ 
awareness of the negative impact that the treatment could have. This behavior was observed in two out of five of 
the endocrine therapy consultations, and it was observed in 8 out of 90 chemotherapy consultations (Engelhardt 
et al. 2016:55-66). Examples of such utterances are: “Every medication has side-effects. Paracetamol has side-
effects, letrozole [a type of endocrine therapy] also has them.”, or “Endocrine therapy is a relatively innocuous 
treatment, you just have to take a little tablet every day.” Even though the oncologist does not explicitly say so, 
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these statements suggest that the treatment is not so important in the grand scheme of things, and denote a 
preference for treatment.  
 
Interestingly, oncologists were inconsistent in their framing of a specific treatment, and the variation did not 
seem due to patient characteristics that would determine the suitability of a treatment for that patient. Generally, 
the impact of endocrine therapy was minimized (Engelhardt et al. 2016:55-66), but in consultations in which 
oncologists seemed keen for the patient to consider chemotherapy, they would bring up that endocrine therapy is 
not as harmless as people commonly think, especially in comparison with chemotherapy (see Example 2). Such 
seemingly different framing of treatment impact was observed in consultations by the same oncologist; thus, it 
was not explained by differences between oncologists.  
 
HERE BOX WITH EXAMPLE 2 
 
2.2.4 Emphasizing the ability to control the side-effects of the treatment. The side-effects of adjuvant systemic 
therapy, particularly chemotherapy, are notorious and feared by patients. Oncologists tended to emphasize that it 
was possible to prevent or control the side-effects of treatment. Frequently stressed was the ability to prevent or 
control chemotherapy-induced nausea (see Example 3 and 4). This behavior was observed in half of the 
consultations analyzed (Engelhardt et al. 2016:55-66). If that medication proved insufficient, it was possible to up 
the dosage or try another type. Thereby, it was implied that the patient had control over the severity and 
management of the side-effect.  
 
HERE BOX WITH EXAMPLE 3 
& 
HERE BOX WITH EXAMPLE 4 
 
2.2.5 Presenting the side-effects after the final treatment decision has been made. A key requirement to patient 
involvement in treatment decision-making is that they are made aware of both the benefits and harms of 
treatment prior to the final treatment decision being made. Informing patients about the side-effects after making 
the decision violates this premise. It also means that the treatment decision was mainly based on the expected 
benefits. Even if the clinician does not explicitly give a treatment recommendation, the fact that the clinician 
seemingly does not deem the side-effects relevant to discuss before a treatment decision is made, could give 
patients the impression that their doctor feels that the expected benefits are worthwhile despite the side-effects.  
 10 
 In two-thirds of the consultations, oncologists provided patients with information about the side-effects 
of treatment after the treatment decision had been made (Engelhardt et al. 2016:55-66). Interestingly, in several 
consultations the way in which the oncologist phrased the purpose of the consultation gave the impression that 
the treatment decision had already been made prior to the consultation (see Example 5). This behavior will 
impede active participation by patients in treatment decision-making. Arguably, patients will only go against the 
perceived treatment decision if they have a strong preference that does not match that decision.  
 
HERE BOX WITH EXAMPLE 5 
 
2.3 Category 2: Presenting treatment recommendations as authorized decisions 
A crucial step to any decision-making consultation is to make patients aware that there is a decision to be made 
and that they have a say in it. However, even if choice awareness is created, patients’ perception of whether they 
have choices can be limited if the phrasing of treatment recommendations is too strong. Below we describe two 
behaviors that might limit patients’ perception of the say they have in treatment decision-making because they 
lend the treatment recommendation a lot of weight. 
 
2.3.1 Presenting treatment as an authorized decision. Presenting treatment as an authorized decision based on 
‘the guideline’: In one out of three consultations, treatment recommendations were phrased as being based on the 
national or international guidelines (Engelhardt et al. 2016:55-66) (see Example 6). 
 Presenting treatment as an authorized ‘we’ decision: In eight out of ten consultations, treatment 
recommendations were phrased as being the result of consensus amongst experts, for example: “We are in favor 
of…”, or “As a profession we have decided that…” (Engelhardt et al. 2016:55-66) (see Example 6). 
 Why should the two behaviors described above be a cause for concern? At first glance these are mere 
factual statements, but they might (unintentionally) limit patient participation in the decision-making process. 
Such phrasing suggests that a group of experts think a certain option is worthwhile. Even if the oncologist 
indicates that the recommendation is not binding and the patient is free to choose a different option that better 
suits her, patients might not feel comfortable declining the perceived best option. They may fear that they will 
not be able to forgive themselves if they go against the recommended course of action and subsequently 
experience a negative outcome. Oncologists might not be aware of the added weight their phrasing imparts to the 
recommendation. From the oncologists’ perspective, such phrasing denotes current practice. Devising treatment 
recommendations is not a solo activity; recommendations are indeed based on discussions in multidisciplinary 
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cancer team meetings, and are guided by those discussions and the guidelines. However, it is important to make 
it clear to patients that all the options presented to them are medically viable options – there is no right choice, 
and preferring a different option to the one recommended does not constitute taking an unnecessary risk. 
 It is important to note here that we do not argue that it is wrong for clinicians to provide patients with an 
explicit treatment recommendation. On the contrary, some patients might find it very useful. Ideally, patients’ 
priorities and goals inform such recommendations, not solely the clinicians’ clinical experiences and guidelines. 
However, the evidence suggests that patient participation during consultations is limited (Couët et al. 2015:542-
61; Kunneman et al. 2015:338-342). Thus, it is likely that recommendations commonly are the result of the 
clinician’s own weighing of the pros and cons, and are not informed by the patient’s views on the pros and cons 
of the treatment options. And, whilst on a group level the assumptions underlying the treatment recommendation 
might hold, they might not hold for an individual patient. 
 
HERE BOX WITH EXAMPLE 6 
 
2.4 Category 3: Creating the illusion of decision control 
The final step in the consultation is that of making the treatment decision. In our consultations, the primary 
treatment decisions that needed to be made were whether to undergo chemotherapy and/or endocrine therapy.  
However, we have observed behaviors in consultations that (unintentionally) shifted the focus away from these 
primary treatment decisions to secondary decisions. For example, the patient could decide whether to start the 
most intensive chemotherapy scheme or a lighter version, not whether to start treatment. The focus of 
information provision was also on that secondary decision, whilst the main decision was implicitly made by their 
oncologist. The primary decision is likely to be based on the treatment recommendation agreed upon during the 
multidisciplinary cancer team meeting. However, that recommendation is agreed upon prior to the oncologist 
meeting the patient, and consequently it might not be in line with patients’ goals and priorities. And once a 
decision has been made, it may be exceedingly difficult for patients to take the initiative to broach the subject of 
revisiting it. 
 
2.4.1 From mild to serious treatment - a gradual decision. The various possible strategies for a specific treatment 
option (e.g., type of chemotherapy regime or total number of courses the regime will consist of) can be presented 
in such a way that the proposed course of treatment seems to be the least aggressive, or invasive, and 
consequently most appealing option. This behavior was observed in one in five consultations (Engelhardt et al. 
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2016:55-66). For example: “In your case we propose a four-course chemotherapy regimen instead of the 
standard six-course regime, which only yields slightly less disease-free survival gain, but is easier to pull 
through”. Due to this manner of presentation the focus is shifted from the primary decision (i.e., whether to 
undergo chemotherapy) towards a secondary decision (i.e., what intensity of chemotherapy to undergo). Again, 
the fact that the option not to undergo treatment is (perhaps unintentionally) not discussed, could suggest to 
patients that their oncologist does not think this option is worth considering.  
 
2.4.2 Having one treatment implicitly tag along with another. A combination of concurrent or consecutive 
treatments is presented as a “package deal”, but the focus in the decision-making process is on one of the 
treatments, and the second treatment is implicitly agreed to as part of the package. In the context of adjuvant 
systemic therapy for early-stage breast cancer, chemotherapy and endocrine therapy can be presented as such, 
but the focus of the consultation is on chemotherapy. It is implicitly assumed that by agreeing to start 
chemotherapy, the patient is agreeing to undergo the whole package, even though endocrine therapy has not been 
(extensively) discussed. In our analyses, this behavior was observed in about one in three consultations 
(Engelhardt et al. 2016:55-66). Technically, the decision about endocrine therapy can be revised once the 
chemotherapy is completed, but patients might not realize this, or might find it difficult to broach the subject if 
the oncologist does not bring it up.  
 
2.4.3 The illusory power to decide. There are instances in which the main treatment decision (i.e., whether to 
start treatment) is implicitly made by the clinician, and patients are given control over a secondary decision. For 
example, the clinician could emphasize that if the side-effects become too much to bear, the patient decides 
whether to stop with treatment or switch to another type of the same treatment (see Example 7). The patient does 
not make the primary treatment decision, but by leaving the decision about terminating or switching treatment in 
the patient’s hands, the illusion is created that she has decisional control. This behavior was observed in half of 
the consultations (Engelhardt et al. 2016:55-66).  
 
HERE BOX WITH EXAMPLE 7 
 
2.5 Category 4: Persuading patients using (clinical) experience 
Clinicians can (inadvertently) steer patients towards a specific treatment option by (overly) emphasizing their 
prior experiences with comparable patients. Given all the uncertainty patients face from the moment they receive 
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their diagnosis, examples from their doctor’s clinical experience can be something to hold on to. Such experience 
can be very powerful for patients and can play an important role in their weighing of the treatment options. The 
phrasing of and context in which such experiences are brought up, can suggest to patients that in their case there 
is a best option, which in turn may limit patients’ own weighing of the pros and cons of treatment with their own 
personal situation in mind.  
 
2.5.1 Making assertions about the patients' personality. The oncologist verbalizes assertions about what the 
patient might or might not be able to handle, her ability to persevere, and her priorities in life in the context of 
treatment. We observed this behavior in one in ten consultations (Engelhardt et al. 2016:55-66). Examples of 
such assertions are: “Some people’s mood changes somewhat [due to endocrine therapy]. That is very rare, you 
do not seem like the type to experience that, but it could happen” or “If you are the type of person that sees 
things as the glass is half full rather than the glass is half empty you will get through it all better. I think you are 
more the type of person that sees things as the glass is half full”. Such statements might suggest to patients that 
their doctor is trying to tell them that they should at least try the treatment, i.e., that the clinician thinks they need 
it.  
 
2.5.2 Deterring vs. encouraging: using others as examples. Using clinical experiences of other patients (i.e., 
frightening or hopeful stories), clinicians can steer patients towards the course of treatment they favor. Phrases 
associated with this behavior are for example: “in my experience, most women… ” or “I have never come 
across…”. Such phrasing could impede patients’ own evaluation of the pros and cons of the various treatment 
options. As a layperson, a patient will be unlikely to go against the oncologist’s experience. We observed this 
behavior in one in ten consultations (Engelhardt et al. 2016:55-66).  
 
2.5.3 Giving the impression that undergoing or foregoing treatment is quite unusual. By emphasizing that it is 
very unusual for a patient with specific characteristics to undergo or forego a specific treatment option, clinicians 
suggest that considering another option is not a good idea from a medical perspective. For example: “It is 
unheard of for patients with HER2-positive disease like yours to forego chemotherapy and trastuzumab”. It 
would take a patient with strong convictions, who is not afraid to carry the responsibility for the potentially 
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negative consequences of her choice, to go against the option her clinician seems to prefer. Most patients might 
not feel comfortable going against what the clinical expert(s) recommend. We observed this behavior in one in 
ten consultations (Engelhardt et al. 2016:55-66). 
 
3. Reflection on potential explanations for the use of implicit persuasion 
In the previous sections, we introduced the construct of implicit persuasion, presented implicitly persuasive 
behaviors, and discussed for each behavior why and how it might derail attempts to involve patients in treatment 
decision-making. Here, we will reflect on potential explanations for the use of implicit persuasion. Based on our 
analysis of consultations (Engelhardt et al. 2016:55-66), we identified five factors we believe play a role in the 
use of implicit persuasion in the context of decision-making consultations. 
 
3.1 Attempts to prevent information overload 
An inexorable difficulty to information provision in clinical practice is that it is usually impossible to discuss all 
potential benefits and harms of the treatment options with patients. Clinicians must make choices about what 
information they disclose to patients, as providing too much information might overwhelm patients, and render 
them unable to utilize the information efficiently (Tversky and Kahneman 1973:207-232).  
 In the absence of guidance, in for example clinical guidelines, the decision about what to disclose is 
likely to be based on what the clinician thinks is relevant for their patient to know. This can vary between 
clinicians, both fueled by the clinician’s own weighing of the benefits and harms in general as well as their 
clinical judgement as to the added value for a specific patient. Indeed, significant variation in the information 
disclosed to patients has been reported in the oncology setting (see Pieterse et al. 2011:e251-e259; Holmes-
Rovner et al. 2015: 999-1009; Kunneman et al. 2015: 39-43). This suggests that between clinicians the weight 
given to the various benefits and harms differs significantly. The disparity in information provided to patients is 
a serious issue. It can be argued that clinicians do not meet their duty to inform patients if patients are not 
minimally made aware of the core set of benefits and harms that is relevant to all. In other words, the minimum 
legal requirement for informed consent is not met.  
 Further, prior to the consultation, for example during the multidisciplinary cancer team meeting, a 
decision is made about which treatment options will be presented to patients. Decision-making in this phase is 
driven by clinical guidelines and by what clinicians deem most suitable given disease and patient characteristics, 
such as disease stage, tumor grade and patient age, and oncologists’ experience with patients with similar 
 15 
characteristics. Patients’ goals and priorities regarding the management of their disease does not play a role 
(Scherr et al. 2017:56-69; Hahlweg et al. 2015:e0139921). If, clinicians do not invest time in exploring what the 
patient’s goals and priorities are during the decision-making consultation with patients, they will not be able to 
gauge whether their assumptions about what is in the patient’s best interest aligns with the patient’s actual 
personal situation. Failing to check these assumptions alongside unbalanced information provision can result in a 
mismatch between patient goals and preferences and the treatment option that is decided on. Indeed, there are 
many reports in the literature showing that adequate exploration of the patient's expectations or ideas about how 
their illness is to be managed is minimal during consultations with patients (Couët et al. 2015:542-61; Pieterse et 
al. 2011:e251-e259; Holmes-Rovner et al. 2015:999-1009; Henry et al. 2015:1757-68; Henselmans et al. 
2017:625-633).  
 
3.2 Lack of awareness of the gap in knowledge between doctors and patients 
Clinicians are aware that they have greater bio-medical knowledge than patients (e.g., about the course of the 
disease with and without treatment), and it is reasonable to assume that the exchange of information during 
consultations focuses on bridging this knowledge gap. However, clinicians might not realize that other aspects 
that are self-evident to them might not be obvious to (all) their patients. For example, clinicians frequently 
present treatment options and do not explicitly inform patients that no treatment is also a viable option (Holmes-
Rovner et al. 2015:999-1009)., When not explicitly listed as an option, some patients might not realize that 
foregoing treatment is a viable option that does not have a significant detrimental effect on their long-term 
survival probabilities.  
 
3.3 Lack of awareness of own preferences 
It is unrealistic to assume that it is possible for clinicians to provide information that is in no way colored by their 
own preferences and beliefs about what is best for patients. Clinicians might not be aware that their choices 
regarding which information to disclose to patients can reflect their own preferences. And clinicians consistently 
(and logically) have been found to prefer the treatment in which they are specialized. For example, in the context 
of prostate cancer, Fowler and colleagues (2000:3217-3222) described that although urologists and radiation 
oncologists were aware that available treatment options generally did not outperform each other, they still tended 
to recommend the treatment they delivered themselves. Also, clinicians’ beliefs about the benefit that makes 
treatment worthwhile are not always in line with the minimum treatment benefits used in guidelines to select 
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patients with whom adjuvant treatment should be discussed (Engelhardt et al. 2015:956-959). Such preferences 
could influence how clinicians phrase information about treatment, for example, through downplaying the 
potential burden caused by the side-effects of treatment.  
 
3.4 Overcorrecting patients’ perception of treatment burden 
Utterances by clinicians we would classify as being implicitly steering often seemed to be attempts to comfort 
patients, alleviate perceived anxiety, or correct misconceptions. For example, language minimizing treatment 
impact was often preceded by patients stating that they felt overwhelmed by it all, or expressing concern about 
whether they would be able to cope with treatment or anxiety about a specific side-effect (e.g., nausea, weight 
gain or mood changes). In the setting we studied, it seems that oncologists’ method of addressing such patient 
utterances was to downplay the impact of treatment to reassure them or assuage their fears. Even though the 
intention is laudable, the key danger is overcorrecting and making it seem that for example the specific side-
effect the patient fears is of no consequence. This could cause patients to underestimate treatment impact, and 
agree to treatment without giving due consideration to the potential costs. Particularly in the case of adjuvant 
endocrine therapy, underestimation of treatment impact could be one of the driving forces behind the suboptimal 
adherence to treatment and early treatment discontinuation reported in the literature; up to as much as 50% of 
patients that start do not complete the full 5-year course of treatment (Hershman et al. 2010:4120-4128; van 
Herk-Sukel et al. 2010:843-851; Wouters et al. 2014:460-467).  
 
3.5 Overestimation of patient’s assertiveness 
Since the paradigm shift from a paternalistic culture to patient-centered care, there is the notion that patients are 
increasingly assertive and will verbalize their views and opinions. This notion might cause too great a reliance on 
patients’ assertiveness during consultations, and lead to clinicians underestimating how much weight their words 
carry. They could fail to realize that even if patients are assertive, in a relationship of dependency such as the 
doctor-patient relationship, particularly in life-threatening disease, it might be difficult for patients to go against 
the doctor’s nudges. Going against their doctor’s perceived preferences could also be difficult for patients as they 




Implicitly persuasive behaviors threaten clinician’s ability to include patients in the decision-making process, 
even if the doctor intend to do so. Going forward, a key step is creating awareness amongst clinicians of 
behaviors that could inadvertently impede patient participation in treatment decision-making, for example by 
incorporating this subject in the medical curriculum and post-graduate courses. In addition to creating awareness, 
providing clinicians with tools to adequately implement the principles of SDM, especially how to explore 
patients’ goals and priorities, and address patients’ emotional needs, will prevent the use of many implicitly 
persuasive behaviors we have described here. It is also worth considering whether instructing clinicians in 
argumentation theory, specifically how to correctly present their arguments, could help improve their 
communication with patients. On a macro-level, much can be gained from the development of core lists of what 
information about treatment options is vital to communicate to all patients.  
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Example 1: Excerpt from a consultation with a 62-year-old patient with stage 2 breast cancer 
 
Oncologist: The chemotherapy itself is not such a problem… of course there are some side-effects that need to be 
discussed calmly. For that you will get an appointment with our nurse, who will explain the side-effects and she will also 
give you some information on paper. If we only briefly discuss the side-effects, I think most important to mention is that 
it causes fatigue and a little bit of nausea. 
Patient: Oh, how awful, I find that [the nausea] so awful. 
Oncologist: The nausea can usually be reduced with medication. 
Patient: Okay. 
Oncologist: Generally, it is fine…… and there is hair loss 
Patient: Is there always hair loss? 
Oncologist: Yes, with this chemotherapy there is. 
Patient: Yes? ……Okay 
Oncologist: Yes… 
Patient: Well, I know what I am up against with this one [the chemotherapy]. 
Oncologist: These are the major side effects, plus the fact that chemotherapy makes you more susceptible to infections. 
Your defenses will be down. That is why we also check a day or two before the chemotherapy is given. [Information about 
blood work done prior to each course of chemotherapy] 
Patient: Uhm… 
Oncologist: So that is important… it is important that you always get in touch if you get a fever. The nurse will also 
explain all this. But it is important that you get in touch because your immune system is compromised, and if you develop 
an infection your body will be less able to fight it. Fortunately, it hardly ever happens, but it could. 
Patient: What a hassle… 
Oncologist: So those are the important things. You always hear dramatic things about chemotherapy, and we will also 
tell you. Generally, things turn out well. 
Example 2: Quote from a consultation with a 67-year-old patient with stage 2 breast cancer 
 
Oncologist: Everyone always thinks that endocrine therapy, that is just little tablets, it’s not such a big deal. But that is 
not the case. That is not the case. What I find particularly difficult is that if the side-effects of the endocrine therapy are 
greater than expected and if you decide to stop [the endocrine treatment], then you won’t have had any treatment. 
Example 3: Quote from a consultation with a 56-year-old patient with stage 1 breast cancer 
 
Oncologist: You can expect nausea. Therefore, as a precaution we will give you medication against the nausea. I cannot 
promise you that you will not get nauseous, but that [whether you get nauseous] also depends a little bit on your 
attitude. Some people get nauseous if they think about the hospital. That we cannot do much about.  
Example 4: Quote from a consultation with a 70-year-old patient with stage 1 breast cancer 
 
Oncologist: Complaints such as nausea or vomiting are usually not so bad. Especially given the anti-nausea tablets we 
give nowadays, it is no longer the case that people get really… well are continuously vomiting. Really, vomiting is no 
longer… a part of it anymore. With the tablets, you should be able to prevent it [vomiting]. 
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Example 6: Quote from a consultation with a 51-year-old patient with stage 1 breast cancer 
 
Oncologist: We advise what the guideline says. The guideline says that it [chemotherapy] is for everyone, that is what 
has been agreed on, on a national level, for whom the expected treatment benefit is 5% or more. Everyone [oncologists] 
thinks it is worthwhile. However, they are not the ones that have to undergo it, they are only the experts. It is up to you 
whether you think it is worthwhile or not. 
Example 7: Quote from a consultation with a 62-year-old patient with stage 1 breast cancer 
 
Oncologist: About the endocrine therapy tablets we often say, just try it. The side-effects really are not so bad that you 
cannot cope with them. And if you really find the hot flushes awful, if you find the misery too awful, then you can always 
stop, then the side-effects will go away. Uhm, … it is not compulsory, but it is something about which we usually say … 




Example 5: Quote from a consultation with a 46-year-old patient with stage 2 breast cancer  
 
Oncologist: After your surgery your case was discussed during the multidisciplinary cancer team meeting, as we call 
it… I am going to talk about the period after the radiotherapy, because you will now start with radiotherapy first. And 
about four weeks after the radiotherapy, you will start with the chemotherapy. 
